U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Description
Curator's Comment: description was created based on several sources, including, http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/050443s036lbl.pdf

Bleomycin is a mixture of cytotoxic glycopeptide antibiotics isolated from a strain of Streptomyces verticillus. Bleomycin has antitumor activity. Bleomycin selectively inhibits the synthesis of deoxyribonucleic acid (DNA). The guanine and cytosine content correlates with the degree of mitomycin-induced cross-linking. At high concentrations of the drug, cellular RNA and protein synthesis are also suppressed. Bleomycin has been shown in vitro to inhibit B cell, T cell, and macrophage proliferation and impair antigen presentation, as well as the secretion of interferon gamma, TNFa, and IL-2. The antibiotic antitumor drugs are cell cycle-nonspecific except for Bleomycin (which has major effects in G2 and M phases).

CNS Activity

Curator's Comment: Bleomycin does not cross the blood-brain barrier.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
BLEOMYCIN SULFATE

Approved Use

Bleomycin for Injection, USP should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to Bleomycin for Injection is poorer in patients with previously irradiated head and neck cancer. Lymphomas: Hodgkin’s disease, non-Hodgkin’s lymphoma. Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin for Injection, USP has also been shown to be useful in the management of: Malignant Pleural Effusion: Bleomycin for Injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions.

Launch Date

1.12924803E11
Primary
BLEOMYCIN SULFATE

Approved Use

Bleomycin for Injection, USP should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to Bleomycin for Injection is poorer in patients with previously irradiated head and neck cancer. Lymphomas: Hodgkin’s disease, non-Hodgkin’s lymphoma. Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin for Injection, USP has also been shown to be useful in the management of: Malignant Pleural Effusion: Bleomycin for Injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions.

Launch Date

1.12924803E11
Primary
BLEOMYCIN SULFATE

Approved Use

Bleomycin for Injection, USP should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to Bleomycin for Injection is poorer in patients with previously irradiated head and neck cancer. Lymphomas: Hodgkin’s disease, non-Hodgkin’s lymphoma. Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin for Injection, USP has also been shown to be useful in the management of: Malignant Pleural Effusion: Bleomycin for Injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions.

Launch Date

1.12924803E11
Primary
BLEOMYCIN SULFATE

Approved Use

Bleomycin for Injection, USP should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to Bleomycin for Injection is poorer in patients with previously irradiated head and neck cancer. Lymphomas: Hodgkin’s disease, non-Hodgkin’s lymphoma. Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin for Injection, USP has also been shown to be useful in the management of: Malignant Pleural Effusion: Bleomycin for Injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions.

Launch Date

1.12924803E11
Primary
BLEOMYCIN SULFATE

Approved Use

Bleomycin for Injection, USP should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to Bleomycin for Injection is poorer in patients with previously irradiated head and neck cancer. Lymphomas: Hodgkin’s disease, non-Hodgkin’s lymphoma. Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin for Injection, USP has also been shown to be useful in the management of: Malignant Pleural Effusion: Bleomycin for Injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions.

Launch Date

1.12924803E11
Primary
BLENOXANE

Approved Use

BLENOXANE should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agent:Squamous Cell Carcinoma, Lymphomas, Testicular Carcinoma, Malignant Pleural Effusion.

Launch Date

1.74355202E11
Primary
BLENOXANE

Approved Use

BLENOXANE should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agent:Squamous Cell Carcinoma, Lymphomas, Testicular Carcinoma, Malignant Pleural Effusion.

Launch Date

1.74355202E11
Primary
BLENOXANE

Approved Use

BLENOXANE should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agent:Squamous Cell Carcinoma, Lymphomas, Testicular Carcinoma, Malignant Pleural Effusion.

Launch Date

1.74355202E11
Primary
BLENOXANE

Approved Use

BLENOXANE should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agent:Squamous Cell Carcinoma, Lymphomas, Testicular Carcinoma, Malignant Pleural Effusion.

Launch Date

1.74355202E11
Primary
BLENOXANE

Approved Use

BLENOXANE should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agent:Squamous Cell Carcinoma, Lymphomas, Testicular Carcinoma, Malignant Pleural Effusion.

Launch Date

1.74355202E11
Primary
BLENOXANE

Approved Use

BLENOXANE should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agent:Squamous Cell Carcinoma, Lymphomas, Testicular Carcinoma, Malignant Pleural Effusion.

Launch Date

1.74355202E11
Primary
BLENOXANE

Approved Use

BLENOXANE should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agent:Squamous Cell Carcinoma, Lymphomas, Testicular Carcinoma, Malignant Pleural Effusion.

Launch Date

1.74355202E11
Primary
BLENOXANE

Approved Use

BLENOXANE should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agent:Squamous Cell Carcinoma, Lymphomas, Testicular Carcinoma, Malignant Pleural Effusion.

Launch Date

1.74355202E11
Primary
BLENOXANE

Approved Use

BLENOXANE should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agent:Squamous Cell Carcinoma, Lymphomas, Testicular Carcinoma, Malignant Pleural Effusion.

Launch Date

1.74355202E11
PubMed

PubMed

TitleDatePubMed
Biochemical effects of bleomycin A2 on Novikoff hepatoma ascites cells.
1975
Ultrastructural study of the effect of bleomycin A2 on the nucleolus and its possibly related cytoplasmic constituents in Novikoff hepatoma cells.
1975 Feb
The effect of bleomycin A2(-Cu) on the proliferation of brain tumor cells and strained epithelial cells in vitro.
1976 Mar 20
Lack of metabolism as the biochemical basis of bleomycin-induced pulmonary toxicity.
1983 May
Renovascular hypertension after combination chemotherapy for testicular cancer.
1988 Jan
Acute vascular toxicity after combination chemotherapy with cisplatin, vinblastine, and bleomycin for testicular cancer.
1988 May
Drug-induced encephalopathy after previous ifosfamide treatment.
1988 Nov 5
Non-Q-wave myocardial infarction associated with bleomycin and etoposide chemotherapy.
1991 Jun
[Loss of ganglion cells in the retina secondary to vincristine therapy].
1992 May
A pilot study on the influence of a corticotropin (4-9) analogue on Vinca alkaloid-induced neuropathy.
1992 Oct
A case of treatment-related myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemotherapy with autologous stem cell transplantation for non-Hodgkin's lymphoma.
2002 Aug
Codon 64 of K-ras gene mutation pattern in hepatocellular carcinomas induced by bleomycin and 1-nitropyrene in A/J mice.
2003
CC-chemokine receptor 2 required for bleomycin-induced pulmonary fibrosis.
2003 Dec 21
Tetrathiomolybdate therapy protects against bleomycin-induced pulmonary fibrosis in mice.
2003 Mar
The prognostic role of CD4+ and CD8+ lymphocytes during chemoimmunotherapy in metastatic melanoma.
2004 Dec
Time-dependent apoptosis of alveolar macrophages from rats exposed to bleomycin: involvement of tnf receptor 2.
2004 Sep 10
Role of Eotaxin-1 (CCL11) and CC chemokine receptor 3 (CCR3) in bleomycin-induced lung injury and fibrosis.
2005 Dec
Effect of rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2 on bleomycin-induced lung injury.
2005 Feb
Effect of Feitai on bleomycin-induced pulmonary fibrosis in rats.
2005 Jan 15
Secondary transitional cell carcinoma and nitrogen mustard treatment.
2005 Jun
Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial.
2007 Aug 10
Are platinum-based chemotherapeutic drugs safe for patients with Charcot-Marie-Tooth disease?
2007 Jun
Effects of curcumin in treatment of experimental pulmonary fibrosis: a comparison with hydrocortisone.
2007 Jun 13
DNA methylation inhibitor 5-Aza-2'-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B.
2008 Jan
PPAR-gamma agonists inhibit profibrotic phenotypes in human lung fibroblasts and bleomycin-induced pulmonary fibrosis.
2008 May
Agents associated with lung inflammation induce similar responses in NCI-H292 lung epithelial cells.
2008 Oct
Epigallocatechin-3-gallate exhibits anti-fibrotic effect by attenuating bleomycin-induced glycoconjugates, lysosomal hydrolases and ultrastructural changes in rat model pulmonary fibrosis.
2009 Jul 15
Effects of erlotinib on lung injury induced by intratracheal administration of bleomycin (BLM) in rats.
2010 Aug
XRCC1 deficiency sensitizes human lung epithelial cells to genotoxicity by crocidolite asbestos and Libby amphibole.
2010 Dec
Pulmonary fibrosis inducer, bleomycin, causes redox-sensitive activation of phospholipase D and cytotoxicity through formation of bioactive lipid signal mediator, phosphatidic acid, in lung microvascular endothelial cells.
2011 Feb
Removal of reactive oxygen species-induced 3'-blocked ends by XPF-ERCC1.
2011 Nov 21
Testing chemical agents with the cytokinesis-block micronucleus cytome assay.
2012
Preventing cleavage of Mer promotes efferocytosis and suppresses acute lung injury in bleomycin treated mice.
2012 Aug 15
Thymoquinone blocks lung injury and fibrosis by attenuating bleomycin-induced oxidative stress and activation of nuclear factor Kappa-B in rats.
2012 Dec 16
Assessment of Brd4 inhibition in idiopathic pulmonary fibrosis lung fibroblasts and in vivo models of lung fibrosis.
2013 Aug
Matrix metalloproteinase Mmp-1a is dispensable for normal growth and fertility in mice and promotes lung cancer progression by modulating inflammatory responses.
2013 May 17
Berberine attenuates bleomycin induced pulmonary toxicity and fibrosis via suppressing NF-κB dependant TGF-β activation: a biphasic experimental study.
2013 May 23
Diallylsulfide attenuates excessive collagen production and apoptosis in a rat model of bleomycin induced pulmonary fibrosis through the involvement of protease activated receptor-2.
2013 Sep 1
Direct activation of ATM by resveratrol under oxidizing conditions.
2014
Distinct mechanisms of cell-kill by triapine and its terminally dimethylated derivative Dp44mT due to a loss or gain of activity of their copper(II) complexes.
2014 Oct 1
Protocatechuic aldehyde ameliorates experimental pulmonary fibrosis by modulating HMGB1/RAGE pathway.
2015 Feb 15
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: Bleomycin can be given intramuscularly, or subcutaneously in Squamous cell carcinoma, non-Hodgkin’s lymphoma, testicular carcinoma, Hodgkin’s disease and as a single dose bolus intrapleural injection (60 units) in Malignant Pleural Effusion.
The main components of Bleomycin for Injection are bleomycins A2 and B2. Squamous cell carcinoma, non-Hodgkin’s lymphoma, testicular carcinoma - 0.25 to 0.50 units/kg (10 to 20 units/m2) given intravenously, intramuscularly, or subcutaneously weekly or twice weekly.
Route of Administration: Other
In Vitro Use Guide
Purified nucleolar DNA was markedly degraded at a concentration of 13 ug/ml by bleomycin A2; bleomycin concentrations 20-30 times greater were required to degrade nucleoplasmic DNA. Whole nuclear DNA was degraded to only a small extent at 13 ug/ml but was markedly degraded at higher bleomycin concentrations.
Substance Class Mixture
Created
by admin
on Wed Jul 05 23:54:31 UTC 2023
Edited
by admin
on Wed Jul 05 23:54:31 UTC 2023
Record UNII
40S1VHN69B
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BLEOMYCIN
HSDB   INN   VANDF   WHO-DD  
INN  
Official Name English
Bleomycin [WHO-DD]
Common Name English
BLEOMYCIN HYDROCHLORIDE [JAN]
Common Name English
BLEOMYCIN [VANDF]
Common Name English
BLENAMAX
Brand Name English
NSC-125066
Code English
BLEOMYCINS
MI  
Common Name English
bleomycin [INN]
Common Name English
BLEOMYCINS [MI]
Common Name English
BLEOMYCIN [IARC]
Common Name English
BLEOMYCIN [HSDB]
Common Name English
BLEOMYCIN HEXAL
Brand Name English
BLEO
Brand Name English
BLEOCIN
Brand Name English
BLEOMYCINS [IARC]
Common Name English
MIXTURE OF CYTOTOXIC GLYCOPEPTIDES PRODUCED BY THE GROWTH OF STREPTOMYCES VERTICILLUS
Common Name English
Classification Tree Code System Code
LIVERTOX NBK548499
Created by admin on Wed Jul 05 23:54:31 UTC 2023 , Edited by admin on Wed Jul 05 23:54:31 UTC 2023
WHO-VATC QL01DC01
Created by admin on Wed Jul 05 23:54:31 UTC 2023 , Edited by admin on Wed Jul 05 23:54:31 UTC 2023
NCI_THESAURUS C2311
Created by admin on Wed Jul 05 23:54:31 UTC 2023 , Edited by admin on Wed Jul 05 23:54:31 UTC 2023
NDF-RT N0000180854
Created by admin on Wed Jul 05 23:54:31 UTC 2023 , Edited by admin on Wed Jul 05 23:54:31 UTC 2023
WHO-ESSENTIAL MEDICINES LIST 8.2
Created by admin on Wed Jul 05 23:54:31 UTC 2023 , Edited by admin on Wed Jul 05 23:54:31 UTC 2023
FDA ORPHAN DRUG 118498
Created by admin on Wed Jul 05 23:54:31 UTC 2023 , Edited by admin on Wed Jul 05 23:54:31 UTC 2023
FDA ORPHAN DRUG 326510
Created by admin on Wed Jul 05 23:54:31 UTC 2023 , Edited by admin on Wed Jul 05 23:54:31 UTC 2023
WHO-ATC L01DC01
Created by admin on Wed Jul 05 23:54:31 UTC 2023 , Edited by admin on Wed Jul 05 23:54:31 UTC 2023
Code System Code Type Description
DRUG CENTRAL
4742
Created by admin on Wed Jul 05 23:54:31 UTC 2023 , Edited by admin on Wed Jul 05 23:54:31 UTC 2023
PRIMARY
CHEBI
3139
Created by admin on Wed Jul 05 23:54:31 UTC 2023 , Edited by admin on Wed Jul 05 23:54:31 UTC 2023
PRIMARY
LACTMED
Bleomycin
Created by admin on Wed Jul 05 23:54:31 UTC 2023 , Edited by admin on Wed Jul 05 23:54:31 UTC 2023
PRIMARY
RXCUI
1622
Created by admin on Wed Jul 05 23:54:31 UTC 2023 , Edited by admin on Wed Jul 05 23:54:31 UTC 2023
PRIMARY RxNorm
EVMPD
SUB00842MIG
Created by admin on Wed Jul 05 23:54:31 UTC 2023 , Edited by admin on Wed Jul 05 23:54:31 UTC 2023
PRIMARY
HSDB
3208
Created by admin on Wed Jul 05 23:54:31 UTC 2023 , Edited by admin on Wed Jul 05 23:54:31 UTC 2023
PRIMARY
ChEMBL
CHEMBL3039590
Created by admin on Wed Jul 05 23:54:31 UTC 2023 , Edited by admin on Wed Jul 05 23:54:31 UTC 2023
PRIMARY
NSC
125066
Created by admin on Wed Jul 05 23:54:31 UTC 2023 , Edited by admin on Wed Jul 05 23:54:31 UTC 2023
PRIMARY
MESH
D001761
Created by admin on Wed Jul 05 23:54:31 UTC 2023 , Edited by admin on Wed Jul 05 23:54:31 UTC 2023
PRIMARY
EPA CompTox
DTXSID1030862
Created by admin on Wed Jul 05 23:54:31 UTC 2023 , Edited by admin on Wed Jul 05 23:54:31 UTC 2023
PRIMARY
CAS
11056-06-7
Created by admin on Wed Jul 05 23:54:31 UTC 2023 , Edited by admin on Wed Jul 05 23:54:31 UTC 2023
PRIMARY
NCI_THESAURUS
C313
Created by admin on Wed Jul 05 23:54:31 UTC 2023 , Edited by admin on Wed Jul 05 23:54:31 UTC 2023
PRIMARY
FDA UNII
40S1VHN69B
Created by admin on Wed Jul 05 23:54:31 UTC 2023 , Edited by admin on Wed Jul 05 23:54:31 UTC 2023
PRIMARY
MERCK INDEX
M2589
Created by admin on Wed Jul 05 23:54:31 UTC 2023 , Edited by admin on Wed Jul 05 23:54:31 UTC 2023
PRIMARY Merck Index
DRUG BANK
DB00290
Created by admin on Wed Jul 05 23:54:31 UTC 2023 , Edited by admin on Wed Jul 05 23:54:31 UTC 2023
PRIMARY
WIKIPEDIA
BLEOMYCIN
Created by admin on Wed Jul 05 23:54:31 UTC 2023 , Edited by admin on Wed Jul 05 23:54:31 UTC 2023
PRIMARY
INN
2721
Created by admin on Wed Jul 05 23:54:31 UTC 2023 , Edited by admin on Wed Jul 05 23:54:31 UTC 2023
PRIMARY
DAILYMED
40S1VHN69B
Created by admin on Wed Jul 05 23:54:31 UTC 2023 , Edited by admin on Wed Jul 05 23:54:31 UTC 2023
PRIMARY
All of the following components must be present:
Related Record Type Details
BINDER->LIGAND
BINDING
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Definition References